Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha-amyrin is a naturally occurring pentacyclic triterpenoid found in various plant species, including the bark of birch and oak trees, and resins from species such as *Protium heptaphyllum*. It is primarily investigated as a research compound for its diverse pharmacological properties, including anti-inflammatory, analgesic, antihyperglycemic, and neuroprotective effects. Preclinical studies suggest that alpha-amyrin may modulate several signaling pathways, such as the activation of extracellular signal-regulated kinase (ERK) and glycogen synthase kinase-3β (GSK-3β) in the hippocampus to ameliorate cognitive impairment. It has also been studied for its potential inhibitory effects on protein kinase A (PKA) and its interaction with cannabinoid receptors (CB1 and CB2), COX-2, and NF-κB. Currently, alpha-amyrin is not under formal pharmaceutical development by any commercial entity and has no regulatory approval for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-amyrin.